|
|
|
| Significance of HIF-1α, VEGF and Bcl-2 Expression in Cervical Carcinoma |
| YU Feng, HAN Chao, HAN Li-na, et al |
| Department of Obstetrics and Gynecology, Maternal and Child Health Family Planning Service Center of Rizhao City,Rizhao 276826,China |
|
|
|
|
Abstract 【Objective】 To explore the expression and significance of hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and B-cell lymphoma-2 (Bcl-2) in cervical carcinoma. 【Methods】 The expression of HIF-1α, VEGF and Bcl-2 in 82 cases of cervical carcinoma and normal cervical tissues was detected by immunohistochemical method. The relationship between the three markers (HIF-1α, VEGF and Bcl-2) and clinical pathological parameters was analyzed. 【Results】 The positive rate of HIF-1α in cervical carcinoma 80.48% (66/82) was higher than that in normal cervical tissues 2.43% (2/82) (P<0.05). The positive rate of VEGF in cervical carcinoma 82.93% (68/82) was higher than that in normal cervical tissues 3.65% (3/82) (P<0.05). The positive rate of Bcl-2 in cervical carcinoma 73.17% (60/82) was higher than that in normal cervical tissues 30.48% (25/82) (P<0.05). The positive expression rates of HIF-1α, and VEGF in cervical carcinoma with differential degree, clinical stage and lymph node metastasis were statistically significant (P<0.05), but not correlated with age, gender and lesion size. The positive expression rate of Bcl-2 wasn't related to those clinical parameters (differential degree, clinical stage, lymph node metastasis, age, gender and lesion size) (P>0.05).According to Pearson correlation analysis, HIF-1α expression was positively correlated with the expression of VEGF and Bcl-2 in cervical cancer tissues (r=0.685, P=0.010; r=0.532, P=0.025, respectively); VEGF was positively correlated with Bcl-2 expression (r=0.584, P=0.033).【Conclusion】 The high expression of HIF-1α, VEGF and Bcl-2 in cervical carcinoma can be used as reference indicators to determine the occurrence and lymph node metastasis of cervical carcinoma.
|
|
Received: 13 March 2018
|
|
|
|
|
|
[1] 杨莉, 程玺. 宫颈癌分子靶向治疗的研究进展[J].中国癌症杂志, 2015,25(1):73-80.
[2] 赵航, 刘东屏. HIF-1α与实体性肿瘤发生及临床关系的研究进展[J].现代肿瘤医学, 2013,21(9):2134-2137.
[3] 陈舒, 罗新, 帅翰林, 等. 宫颈癌组织中的PTEN,VEGF和CD105的表达及临床意义[J].现代生物医学进展, 2017,17(9):1696-1699.
[4] 孙炯. 检测凋亡抑制因子Bcl-2、Cox-2表达水平在评估早期宫颈癌患者预后的价值分析[J].中国妇幼保健, 2014,29(35):5789-5791.
[5] 马宗丽, 沙红兰, 肖黎明,等. HIF-1α、CAⅨ和Glut-1在宫颈癌组织中的表达及意义[J].江苏医药, 2016, 42(17):1911-1914.
[6] 秦承东, 任正刚, 汤钊猷. 缺氧微环境在肿瘤进展中的作用[J].肿瘤, 2016,36(1):96-102.
[7] 张静. HIF-1α表达与宫颈癌的关系探讨[J].辽宁中医药大学学报, 2013,23(2):130-131.
[8] 娄英, 梁文倩. 宫颈癌患者HIF-1α、VEGF、MVD、CXCL12/CXCR4的表达及其预后研究[J].中国妇幼保健, 2016,31(20):4135-4138.
[9] A Y, Li Y, Zhao S. The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma[J].Oncol Lett,2018,15(2):2534-2540.
[10] 朱燕, 杨其昌, 刘宏斌, 等. 骨桥蛋白、survivin及bcl-2在宫颈病变中的表达及临床意义[J].肿瘤防治研究, 2013,40(1):83-86.
[11] 何勇, 李明武, 王华新, 等. HIF-1α和Bcl-2在肺腺癌中的表达和相关性[J].现代肿瘤医学, 2012,20(1):68-70. |
|
|
|
2018, Vol. 35 
